Figure 5From: RETRACTED ARTICLE: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumorEGFR kinase inhibitor gefitinib decreased STS26T MPNST tumor cell proliferation by blocking the PI3K/AKT and MAPK pathways. (A) The IC50 of gefitinib in tumor cells was about 10 μM. (B) At a 10-μM concentration, gefitinib significantly decreased tumor cell proliferation compared with the MOCK and DMSO controls. (C) Gefitinib significantly decreased activation of EGFR. (D) Gefitinib significantly decreased activation of the PI3K/AKT and MAPK signaling pathways. * indicate P-values <0.05.Back to article page